Analysts forecast that NewLink Genetics Corp (NASDAQ:NLNK) will post earnings per share (EPS) of ($0.69) for the current quarter, Zacks reports. Three analysts have made estimates for NewLink Genetics’ earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.60). NewLink Genetics posted earnings per share of ($0.46) during the same quarter last year, which would indicate a negative year over year growth rate of 50%. The company is scheduled to announce its next quarterly earnings report on Tuesday, February 27th.
On average, analysts expect that NewLink Genetics will report full-year earnings of ($2.65) per share for the current financial year, with EPS estimates ranging from ($2.80) to ($2.55). For the next financial year, analysts forecast that the business will report earnings of ($2.40) per share, with EPS estimates ranging from ($3.02) to ($1.62). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow NewLink Genetics.
A number of brokerages recently weighed in on NLNK. Bank of America began coverage on shares of NewLink Genetics in a research note on Friday, October 13th. They set a “buy” rating and a $22.00 price target for the company. BidaskClub upgraded shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. Jefferies Group decreased their price target on shares of NewLink Genetics from $26.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, November 3rd. Stifel Nicolaus increased their price target on shares of NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Finally, Cantor Fitzgerald restated a “buy” rating and set a $26.00 price objective on shares of NewLink Genetics in a research report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $23.29.
A number of institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company raised its position in NewLink Genetics by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after buying an additional 556 shares during the last quarter. Advisor Group Inc. raised its position in NewLink Genetics by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after buying an additional 600 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of NewLink Genetics by 1.8% in the 2nd quarter. Wells Fargo & Company MN now owns 165,791 shares of the biotechnology company’s stock valued at $1,219,000 after purchasing an additional 2,865 shares in the last quarter. State Street Corp increased its holdings in shares of NewLink Genetics by 1.2% in the 2nd quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after purchasing an additional 4,630 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its holdings in shares of NewLink Genetics by 21.5% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 27,972 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 4,955 shares in the last quarter. Institutional investors own 52.68% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/07/brokerages-expect-newlink-genetics-corp-nlnk-to-announce-0-69-earnings-per-share.html.
About NewLink Genetics
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.